Egetis Strengthens Rare Disease Push With New Chief Medical Officer

The latest announcement is out from Egetis Therapeutics AB ( (SE:EGTX) ).

Egetis Therapeutics has appointed Tiago Nunes as Chief Medical Officer, effective May 1, 2026, bringing in a seasoned clinical development leader with a strong track record in advancing rare disease therapies through approval and launch, including at Mirum Pharmaceuticals. He succeeds outgoing CMO Kristina Sjöblom Nygren, who will stay on until U.S. approval of Emcitate to ensure a smooth transition, underscoring Egetis’ focus on strengthening medical leadership as it prepares for a potential U.S. launch of Emcitate and pursues further label expansion opportunities in rare endocrine disorders.

The appointment comes as Egetis accelerates its transformation into a commercial-stage rare disease company, following EU approval and German launch of Emcitate and the FDA’s Priority Review of its U.S. filing. By bringing in Nunes’ experience with rare disease portfolios and regulatory milestones, the company aims to reinforce its clinical and medical affairs capabilities, which could sharpen its competitive positioning in the orphan drug market and support long-term growth around both Emcitate and its broader pipeline.

The most recent analyst rating on (SE:EGTX) stock is a Hold with a SEK5.50 price target. To see the full list of analyst forecasts on Egetis Therapeutics AB stock, see the SE:EGTX Stock Forecast page.

More about Egetis Therapeutics AB

Egetis Therapeutics AB is a Stockholm-based pharmaceutical company focused on late-stage development and commercialization of treatments for serious diseases with significant unmet medical needs in the orphan drug segment. Its lead candidate Emcitate (tiratricol) targets monocarboxylate transporter 8 (MCT8) deficiency, already approved in the EU, while a U.S. New Drug Application is under Priority Review with an FDA decision expected in late 2026.

Average Trading Volume: 842,145

Technical Sentiment Signal: Buy

Current Market Cap: SEK2.24B

See more insights into EGTX stock on TipRanks’ Stock Analysis page.